Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President & CFO | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 449,434 |
Ending reported balance
After 2026-03-04 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2026-03-03 · Exercise / conversion · Acquired 45,290 · Balance 167,442 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2026-03-03 · Tax withholding · Disposed 16,182 · Balance 151,260 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Row 3 · 2026-03-03 · Exercise / conversion · Acquired 57,339 · Balance 208,599 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 4 · 2026-03-03 · Tax withholding · Disposed 24,251 · Balance 184,348 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Row 5 · 2026-03-03 · Exercise / conversion · Acquired 28,538 · Balance 212,886 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 6 · 2026-03-03 · Tax withholding · Disposed 14,298 · Balance 198,588 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Row 7 · 2026-03-03 · Exercise / conversion · Acquired 458,716 · Balance 657,304 F4: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Row 8 · 2026-03-03 · Tax withholding · Disposed 229,817 · Balance 427,487 F5: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Row 9 · 2026-03-04 · Exercise / conversion · Acquired 43,982 · Balance 471,469 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 10 · 2026-03-04 · Tax withholding · Disposed 22,035 · Balance 449,434 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-03 · Exercise / conversion · Disposed 45,290 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,340 |
Reported balance
After 2026-03-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-03 · Exercise / conversion · Disposed 57,339 · Balance 57,340 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 85,617 |
Reported balance
After 2026-03-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-03 · Exercise / conversion · Disposed 28,538 · Balance 85,617 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8: On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 87,963 |
Reported balance
After 2026-03-04 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-03-04 · Exercise / conversion · Disposed 49,982 · Balance 87,963 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9: On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-03 · Exercise / conversion · Disposed 458,716 · Balance 0 F4: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.
F5: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.
F6: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F7: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F8: On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F9: On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kadmon Holdings, Inc.
Report date November 09, 2021 · Filed November 09, 2021
Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2027-06-29 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2028-07-27 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2029-05-15 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2030-05-13 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-09 · Disposition to issuer · Disposed 102,040 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2031-05-12 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-09 · Disposition to issuer · Disposed 116,370 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 49,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · derivative · entry 15 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,963 Underlying: Class A Common Stock · 49,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F9 · derivative.expiration_date: On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 22,035 | $13.30 | $293,065.50 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 10 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,434 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 43,982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 9 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 458,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · derivative · entry 14 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 458,716 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 28,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · derivative · entry 13 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,617 Underlying: Class A Common Stock · 28,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8 · derivative.exercise_date: On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 57,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · derivative · entry 12 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,340 Underlying: Class A Common Stock · 57,339 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 45,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · derivative · entry 11 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 45,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 229,817 | $13.31 | $3,058,864.27 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 8 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,487 F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 458,716 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 7 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 14,298 | $13.31 | $190,306.38 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 6 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,588 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 28,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 5 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 24,251 | $13.31 | $322,780.81 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 4 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,348 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 57,339 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 3 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 16,182 | $13.31 | $215,382.42 |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,260 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 45,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015239 · wk-form4_1772746314.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:28 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 72,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013887 · wk-form4_1772573278.xml · derivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,622 Underlying: Class A Common Stock · 72,622 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:28 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 72,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013887 · wk-form4_1772573278.xml · derivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,622 Underlying: Class A Common Stock · 72,622 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027. Read SEC document |
| August 15, 2025 Filed Aug 15, 2025 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 219,159 | $9.43 | $2,066,669.37 |
DisclosureSEC source: 0001723128-25-000051 · wk-form4_1755289808.xml · nonDerivative · entry 3 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,152 F3 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 119,206 | $9.30 | $1,108,615.80 |
DisclosureSEC source: 0001723128-25-000051 · wk-form4_1755289808.xml · nonDerivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,311 F2 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.34 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 161,365 | $9.22 | $1,487,785.30 |
DisclosureSEC source: 0001723128-25-000051 · wk-form4_1755289808.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,517 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 100,000 | $8.91 | $891,000.00 |
DisclosureSEC source: 0001628280-25-011303 · wk-form4_1741382230.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 621,882 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.84 to $8.98 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 43,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · derivative · entry 14 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,945 Underlying: Class A Common Stock · 43,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F11 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F11 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 22,497 | $8.84 | $198,873.48 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · nonDerivative · entry 8 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,882 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 43,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · nonDerivative · entry 7 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 114,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · derivative · entry 13 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,154 Underlying: Class A Common Stock · 114,155 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F10 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026. F10 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 228,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · derivative · entry 12 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,310 Underlying: Class A Common Stock · 228,310 shares Expires not disclosed F8 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 114,155 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance period. F9 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 114,155 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance period. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 181,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · derivative · entry 11 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 181,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 57,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · derivative · entry 10 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,679 Underlying: Class A Common Stock · 57,340 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 45,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · derivative · entry 9 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,290 Underlying: Class A Common Stock · 45,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 92,663 | $8.76 | $811,727.88 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · nonDerivative · entry 6 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,398 F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 181,159 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · nonDerivative · entry 5 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 793,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 24,374 | $8.76 | $213,516.24 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · nonDerivative · entry 4 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,902 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 57,340 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · nonDerivative · entry 3 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 636,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 16,373 | $8.76 | $143,427.48 |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · nonDerivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,936 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:53 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 45,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010713 · wk-form4_1741222400.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:59 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 36,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010115 · wk-form4_1741132756.xml · derivative · entry 3 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 36,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:59 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 13,494 | $8.67 | $116,992.98 |
DisclosureSEC source: 0001628280-25-010115 · wk-form4_1741132756.xml · nonDerivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,019 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:59 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010115 · wk-form4_1741132756.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 20:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 87,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-011223 · wk-form4_1710447463.xml · derivative · entry 3 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 87,720 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 20:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 30,790 | $5.31 | $163,494.90 |
DisclosureSEC source: 0001628280-24-011223 · wk-form4_1710447463.xml · nonDerivative · entry 2 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,316 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 20:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 87,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-011223 · wk-form4_1710447463.xml · nonDerivative · entry 1 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 558,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 351,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · derivative · entry 11 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,852 Underlying: Class A Common Stock · 351,852 shares Expires not disclosed F8 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 175,926 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. F9 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 175,926 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 175,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · derivative · entry 10 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,926 Underlying: Class A Common Stock · 175,926 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 4, 2025. F7 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 4, 2025. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 57,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · derivative · entry 9 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,019 Underlying: Class A Common Stock · 57,339 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 45,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · derivative · entry 8 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,580 Underlying: Class A Common Stock · 45,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 20,126 | $5.47 | $110,089.22 |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · nonDerivative · entry 6 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,386 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 57,339 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · nonDerivative · entry 5 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 15,897 | $5.47 | $86,956.59 |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · nonDerivative · entry 4 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 433,173 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 45,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · nonDerivative · entry 3 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 36,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008979 · wk-form4_1709675759.xml · derivative · entry 7 Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,197 Underlying: Class A Common Stock · 36,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.